Biosimilars Business Roundup for June 2023—Podcast Edition
Season 6 Episode 12 · Jul 02, 2023, 11:00 AM
Share
Subscribe
On this episode, we’re going to be recapping some of the biggest stories in the business space regarding biosimilars, including adalimumab preparation, partnerships for commercialization, and more.
Show notes
Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar
Roundup: Coherus Resolves AbbVie Dispute; Bio-Thera Solutions and Celltrion Expand Respective Partnerships
Eye on Pharma: First PBM to Cover Yusimry; Celltrion to Test Ocrevus Biosimilar; Another Stelara Settlement
The Age of Adalimumab Is Upon Us: How Stakeholders Can Prepare
Alvotech, Advanz Pharma Extend Partnership for Biosimilars in Europe
Medicare 340B Program May Be Reducing Biosimilar Uptake
Sandoz Roadmap Aims to Increase Worldwide Biosimilar Adoption by 2030
Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar
Roundup: Coherus Resolves AbbVie Dispute; Bio-Thera Solutions and Celltrion Expand Respective Partnerships
Eye on Pharma: First PBM to Cover Yusimry; Celltrion to Test Ocrevus Biosimilar; Another Stelara Settlement
The Age of Adalimumab Is Upon Us: How Stakeholders Can Prepare
Alvotech, Advanz Pharma Extend Partnership for Biosimilars in Europe
Medicare 340B Program May Be Reducing Biosimilar Uptake
Sandoz Roadmap Aims to Increase Worldwide Biosimilar Adoption by 2030